News Releases

Q2 Business and Financial Highlights: Net Sales were $80.9 Million Gross Margin was 18%, Adjusted Gross Margin was 19% Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two...

Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m....

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett...

--Announces Positive Animal PK Study Results of Insulin Aspart Versus US NovoLog®-- --Analysis of Pivotal Trial Results of Insulin Glargine Nearly Completed, BLA Filing Timeline Slightly Delayed,...

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its...

Q1 Business and Financial Highlights: Net Sales were $75.1 Million Gross Margin 17%, Adjusted Gross Margin 18% Net Sales, Gross Margin and Adjusted Gross Margin Increased from Preceding Quarter...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, after the market closes. Lannett...

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the US Food and Drug Administration (FDA) to manufacture Numbrino®, the company's branded topical anesthetic...

-Companies Entered Into a Separate Private Label Agreement for Certain Other Lannett Generic Products- PHILADELPHIA, Oct. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced...

No Reported Serious Adverse Events; Topline Results Expected Later This Year TREVOSE, Pa., Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that subject dosing has...